Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 183

Results For "RAT"

10048 News Found

Bayer posts strong Q1 2026 results as Crop Science surge lifts earnings & outlook
News | May 14, 2026

Bayer posts strong Q1 2026 results as Crop Science surge lifts earnings & outlook

Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros


Shilpa Medicare signs long-term CDMO pact with NXI Therapeutics to expand global biotech push
News | May 14, 2026

Shilpa Medicare signs long-term CDMO pact with NXI Therapeutics to expand global biotech push

Shilpa will deliver end-to-end services including CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support


Merck KGaA raises 2026 outlook as life science & AI chip boom power strong Q1 growth
News | May 14, 2026

Merck KGaA raises 2026 outlook as life science & AI chip boom power strong Q1 growth

The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion


Pfizer scores landmark EU approval for  hemophilia drug HYMPAVZI
Drug Approval | May 14, 2026

Pfizer scores landmark EU approval for hemophilia drug HYMPAVZI

The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy


Suven Life Sciences reaches 76% milestone in Phase 3 masupirdine trial for Alzheimer’s agitation
Clinical Trials | May 14, 2026

Suven Life Sciences reaches 76% milestone in Phase 3 masupirdine trial for Alzheimer’s agitation

The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies


AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX
interviews | May 13, 2026

AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX

We are building an AI-native operating system for pharma sales and distribution


Actio Biosciences launches Phase 1b/2 trial for ultra-rare pediatric epilepsy therapy
News | May 13, 2026

Actio Biosciences launches Phase 1b/2 trial for ultra-rare pediatric epilepsy therapy

The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process


Industry-academia partnership expands access to advanced life sciences analytics for Indian researchers
News | May 13, 2026

Industry-academia partnership expands access to advanced life sciences analytics for Indian researchers

High-resolution analytical platforms from Agilent Technologies will be made available through C-CAMP’s shared infrastructure model under expanded collaboration